CervoMed's neflamapimod receives UK innovation passport for DLB

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. NVDA
5. STZ
6. MSFT
7. SPY
8. SKYD
9. IBM
10. CRWV

Go back to CervoMed's neflamapimod receives UK innovation passport for DLB

CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

August 4, 2026 5:15 AM EDT

Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines

Neflamapimod selected for the ILAP by joint consensus recognized for being an innovative therapy that addresses a condition of high unmet need, with the demonstrated potential to offer a major therapeutic advantage in DLB treatment

Program provides CervoMed with early and coordinated guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA), the National Health System (NHS), and health technology assessment (HTA) bodies

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) --... More